MMP10 Promotes Efficient Thrombolysis After Ischemic Stroke in Mice with Induced Diabetes
Diabetes is an important risk factor for ischemic stroke (IS). Tissue-type plasminogen activator (tPA) has been associated with less successful revascularization and poor functional outcome in diabetes. We assessed whether a new thrombolytic strategy based on MMP10 was more effective than tPA in a murine IS model of streptozotocin (STZ)-induced diabetes. Wild-type mice were administered a single dose of streptozotocin (STZ) (180 mg/kg) to develop STZ-induced diabetes mellitus. Two weeks later, IS was induced by thrombin injection into the middle cerebral artery and the effect of recombinant MMP10 (6.5 μg/kg), tPA (10 mg/kg) or tPA/MMP10 on brain damage and functional outcome were analysed. Motor activity was assessed using the open field test. Additionally, we studied plasminogen activator inhibitor-1 (PAI-1) and thrombin-antithrombin complex levels (TAT) by ELISA and oxidative stress and blood-brain barrier (BBB) integrity by immunohistochemistry and western blot. MMP10 treatment was more effective at reducing infarct size and neurodegeneration than tPA 24 h and 3 days after IS in diabetic mice. Locomotor activity was impaired by hyperglycemia and ischemic injury, but not by the thrombolytic treatments. Additionally, TAT, oxidative stress and BBB permeability were reduced by MMP10 treatment, whereas brain bleeding or PAI-1 expression did not differ between treatments. Thrombolytic treatment with MMP10 was more effective than tPA at reducing stroke and neurodegeneration in a diabetic murine model of IS, without increasing haemorrhage. Thus, we propose MMP10 as a potential candidate for the clinical treatment of IS in diabetic patients.
KeywordsFibrinolysis Thrombosis Stroke, diabetes mellitus Matrix metalloproteinases
We thank Lara Montori for the help with the experimental work and Rosa Tordera and Mikel Aleixo from Pharmacology and Toxicology Department, University of Navarra for their technical assistance with behavioural tests.
MNO participated in the design of the project, experimental work, statistical analysis, and wrote, reviewed, and edited the manuscript; CR participated in the design of the project and reviewed the manuscript. AS was in charge of the animal experiments; MB performed histological studies; OR participated in the design of the project and reviewed the manuscript; ET participated in the statistical analysis and reviewed the manuscript; BZ participated in the design of the project and reviewed the manuscript; JAR participated in the design of the project and reviewed the manuscript; JAP participated in the design of the project, supervised the work, and edited and reviewed the manuscript; RM participated in the design of the project and edited and reviewed the manuscript; JO was in charge of the whole project design, supervised the work, and wrote, edited, and reviewed this manuscript.
This work was supported by the Ministerio de Economía y Competitividad, Instituto de Salud Carlos III [FIS PI15/01807] and Federal Ministry of Education and Research (FEDER) funds; grants from the Spanish Society of Thrombosis and Haemostasis (SETH), Navarra Government (02/2015), Patrimonio Praga (Mexico) and Virto Group (Navarra, Spain); and PhD scholarship from the Asociación de Amigos de la Universidad de Navarra (ADA).
Compliance with Ethical Standards
Experiments were performed in accordance with European Communities Council Directive guidelines (2010/63/EU) for the care and use of laboratory animals and were approved by the University of Navarra Animal Research Review Committee.
Conflict of Interest
The authors declare that they have no conflict of interest.
All animal experiments were performed in accordance with European Communities Council Directive guidelines (2010/63/EU) for the care and use of laboratory animals and were approved by the University of Navarra Animal Research Review Committee.
- 9.Kamada H, Yu F, Nito C, Chan PH. Influence of hyperglycemia on oxidative stress and matrix metalloproteinase-9 activation after focal cerebral ischemia/reperfusion in rats: relation to blood-brain barrier dysfunction. Stroke. 2007;38(3):1044–9. https://doi.org/10.1161/01.STR.0000258041.75739.cb.Google Scholar
- 10.Vila N, Castillo J, Davalos A, Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke. 2000;31(10):2325–9.Google Scholar
- 12.Ceriello A, Novials A, Ortega E, Pujadas G, La Sala L, Testa R, et al. Hyperglycemia following recovery from hypoglycemia worsens endothelial damage and thrombosis activation in type 1 diabetes and in healthy controls. Nutr Metab Cardiovasc Dis. 2014;24(2):116–23. https://doi.org/10.1016/j.numecd.2013.05.003.Google Scholar
- 13.Fernandez-Cadenas I, Mendioroz M, Munuera J, Alvarez-Sabin J, Rovira A, Quiroga A, et al. Lower concentrations of thrombin-antithrombin complex (TAT) correlate to higher recanalisation rates among ischaemic stroke patients treated with t-PA. Thromb Haemost. 2009;102(4):759–64. https://doi.org/10.1160/TH08-06-0398.Google Scholar
- 18.Rodriguez JA, Orbe J, Martinez de Lizarrondo S, Calvayrac O, Rodriguez C, Martinez-Gonzalez J, et al. Metalloproteinases and atherothrombosis: MMP-10 mediates vascular remodeling promoted by inflammatory stimuli. Front Biosci. 2008;13:2916–21.Google Scholar
- 19.Orbe J, Barrenetxe J, Rodriguez JA, Vivien D, Orset C, Parks WC, et al. Matrix metalloproteinase-10 effectively reduces infarct size in experimental stroke by enhancing fibrinolysis via a thrombin-activatable fibrinolysis inhibitor-mediated mechanism. Circulation. 2011;124(25):2909–19. https://doi.org/10.1161/CIRCULATIONAHA.111.047100.Google Scholar
- 20.Rodriguez JA, Sobrino T, Lopez-Arias E, Ugarte A, Sanchez-Arias JA, Vieites-Prado A, et al. CM352 Reduces brain damage and improves functional recovery in a rat model of intracerebral hemorrhage. J Am Heart Assoc. 2017;6(6) https://doi.org/10.1161/JAHA.117.006042.
- 21.Roncal C, Martinez de Lizarrondo S, Salicio A, Chevilley A, Rodriguez JA, Rosell A, et al. New thrombolytic strategy providing neuroprotection in experimental ischemic stroke: MMP10 alone or in combination with tissue-type plasminogen activator. Cardiovasc Res. 2017;113(10):1219–29. https://doi.org/10.1093/cvr/cvx069.Google Scholar
- 22.Rosell A, Ortega-Aznar A, Alvarez-Sabin J, Fernandez-Cadenas I, Ribo M, Molina CA, et al. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke. 2006;37(6):1399–406. https://doi.org/10.1161/01.STR.0000223001.06264.af.Google Scholar
- 24.Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870–947. https://doi.org/10.1161/STR.0b013e318284056a.Google Scholar
- 32.Ning R, Chopp M, Yan T, Zacharek A, Zhang C, Roberts C, et al. Tissue plasminogen activator treatment of stroke in type-1 diabetes rats. Neuroscience. 2012;222:326–32. https://doi.org/10.1016/j.neuroscience.2012.07.018.Google Scholar
- 34.Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003;107(4):598–603.Google Scholar
- 39.Liu J, Jin X, Liu KJ, Liu W. Matrix metalloproteinase-2-mediated occludin degradation and caveolin-1-mediated claudin-5 redistribution contribute to blood-brain barrier damage in early ischemic stroke stage. J Neurosci. 2012;32(9):3044–57. https://doi.org/10.1523/JNEUROSCI.6409-11.2012.Google Scholar